Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Combination therapy
US8961970B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8961970-B2 |
| Application number | US-201313799706-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 13, 2013 |
| Priority date | Mar 20, 2012 |
| Publication date | Feb 24, 2015 |
| Grant date | Feb 24, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a pharmaceutical combination comprising a MEK inhibitor compound 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide or a pharmaceutically acceptable salt thereof and the IGF1R inhibitor ANTIBODY A, a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of a therapeutically effective amount of such combination to a subject in need thereof, and uses of such combination for the treatment of cancer.
First claim
Opening claim text (preview).
We claim: 1. A method of treating cancers expressing insulin-like growth factor-1 receptor (IGF1R) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of (a) the compound 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide (COMPOUND A) or a pharmaceutically acceptable salt thereof; and (b) an antibody that specifically binds to insulin-like growth factor-1 receptor (IG…
Assignees
Inventors
Classifications
- A61P35/00Primary
Human Necessities · mapped topic
- A61K39/3955Primary
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8961970B2 cover?
- The present invention relates to a pharmaceutical combination comprising a MEK inhibitor compound 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide or a pharmaceutically acceptable salt thereof and the IGF1R inhibitor ANTIBODY A, a pharmaceutical composition comprising such combination, methods for treating cancer comprising administr…
- Who is the assignee on this patent?
- Huang Xizhong, Peters Malte, Gansert Jennifer Lorraine, and 5 more
- What technology area does this patent fall under?
- Primary CPC classification A61P35/00. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).